ASH 2014 | Recent advances in the clinical management of myeloma
David Avigan
• 6 Dec 2014
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr David Avigan (Harvard Medical School, Boston, MA) discusses recent investigational advances in the management of multiple myeloma.
Novel biological therapies, including proteasome inhibitors and immunomodulatory drugs, have improved patient outcomes, but disease progression remains an issue. An integration of existing approaches, including autologous stem cell transplantation, with newer approaches is recommended. Highlight presentations include topics in anti-CS1 humanized monoclonal antibody, elotuzumab, anti-CD38 monoclonal antibody, daratumumab, PD1-pathway inhibition, tumour vaccines and chimeric antigen receptor (CAR) T-cell immunotherapy.
